Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Trial Profile

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PRIME
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 24 Jul 2021 Results of assessing the analysis of circulating immune biomarkers among racial subgroups of Black and white men with metastatic castration-resistant prostate cancer treated with sipuleucel-t, published in the Journal of the National Cancer Institute.
    • 04 Jun 2019 Results assessing antigen (Ag) spread and overall survival in real-world patients from this study, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jul 2017 Status changed from recruiting to discontinued due to Completion of 3yr follow up.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top